信用等级通知书 东方金诚债跟踪评字【2025】0678 号 厦门金达威集团股份有限公司： 东方金诚国际信用评估有限公司根据跟踪评级安排对贵公司及"金 威转债"的信用状况进行了跟踪评级，经信用评级委员会评定，此 次跟踪评级维持贵公司主体信用等级为 AA，评级展望为稳定，同 时维持"金威转债"的信用等级为 AA。 东方金诚国际信用评估有限公司 信评委主任 二〇二五年十月二十三日 东方金诚债跟踪评字【2025】0678 号 信用评级报告声明 为正确理解和使用东方金诚国际信用评估有限公司（以下简称"东方金诚"）出具的 信用评级报告（以下简称"本报告"），本公司声明如下： 1.本次评级为委托评级，东方金诚与评级对象不存在任何影响本次评级行为独立、客 观、公正的关联关系，本次项目评级人员与评级对象之间亦不存在任何影响本次评级 行为独立、客观、公正的关联关系。 2.本次评级中，东方金诚及其评级人员遵照相关法律、法规及监管部门相关要求，充 分履行了勤勉尽责和诚信义务，有充分理由保证本次评级遵循了真实、客观、公正的 原则。 3.本评级报告的结论，是按照东方金诚的评级流程及评级标准做出的独立判断，未受 评级对象和第三方组织或个人 ...

Core Viewpoint - The company reported stable sales for its NMN and ergothioneine products, with ergothioneine showing strong performance during the initial phase of the Double Eleven sales event [1] Group 1 - The company responded to investor inquiries regarding the sales performance of NMN and ergothioneine products [1] - Ergothioneine has gained significant attention this year and has performed exceptionally well in the ongoing Double Eleven sales [1]

Core Viewpoint - The company Jin Dawei (002626.SZ) is steadily advancing its market presence for related products in mainstream e-commerce channels, with positive market feedback for its new product, Ergothioneine, which has garnered significant attention this year [1] Group 1 - The company is actively expanding its market layout in mainstream e-commerce channels [1] - Ergothioneine is highlighted as a new product that has received considerable attention and positive feedback in the market [1]

Group 1 - The core viewpoint of the article highlights that Jindawei (002626.SZ) is steadily advancing its market layout for related products in mainstream e-commerce channels [1] - The new product, Ergothioneine, has garnered significant attention this year and has received positive market feedback [1]

Group 1: Event Overview - The 8th China International Import Expo (CIIE) will be held in Shanghai from November 5 to 10, 2025, with a theme of "New Era, Shared Future" [1] - The exhibition area is expected to exceed 360,000 square meters, with participation from over 150 countries and regions, maintaining a participation rate of over 70% from Fortune 500 and industry-leading companies [1] - This year's expo will feature a product zone for least developed countries that have established diplomatic relations with China, expanding the existing African product zone [1] Group 2: Key Exhibitors and Sectors - Notable participating companies include Yushutech, Pop Mart, Jindawei, and Longan Automobile, among others [5] - The expo will showcase various sectors, including medical equipment and healthcare products, with participation from 700 Fortune 500 pharmaceutical companies and the top 10 medical equipment companies [9] - The automobile and smart mobility sector will feature 300 Fortune 500 exhibitors [11] Group 3: Related Conferences and Activities - The expo will host significant conferences such as the "Digital Economy Empowerment" forum and the "China-Latin America Economic and Trade Cooperation Think Tank Forum" [1] - Other notable events include discussions on intellectual property protection and the internationalization of enterprises, highlighting the importance of innovation and collaboration [1] Group 4: Trade Performance Insights - In September, China's import and export growth rates exceeded expectations, with a notable rebound in imports, particularly in machinery and electrical products [2] - The strong rebound in trade reflects the resilience of China's foreign trade amid tariff disruptions, reinforcing its position as a global manufacturing hub [2]

Core Viewpoint - Jindawei's stock price has shown significant growth this year, with a notable increase in revenue and net profit, indicating strong financial performance and investor interest [1][2]. Group 1: Stock Performance - As of October 21, Jindawei's stock price increased by 2.18% to 21.55 CNY per share, with a total market capitalization of 13.144 billion CNY [1]. - Year-to-date, Jindawei's stock price has risen by 46.60%, with a 9.39% increase over the last five trading days and a 12.01% increase over the last 20 days [1]. Group 2: Financial Performance - For the first half of 2025, Jindawei reported a revenue of 1.728 billion CNY, representing a year-on-year growth of 13.46%, and a net profit of 247 million CNY, which is a 90.12% increase compared to the previous year [2]. - Since its A-share listing, Jindawei has distributed a total of 2.761 billion CNY in dividends, with 488 million CNY distributed over the last three years [3]. Group 3: Shareholder and Institutional Holdings - As of June 30, 2025, Jindawei had 40,700 shareholders, a decrease of 4.30% from the previous period, with an average of 14,976 circulating shares per shareholder, an increase of 4.50% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 1.5915 million shares, and Southern CSI 1000 ETF, which increased its holdings by 521,500 shares [3].

Investment Rating - The report maintains a positive outlook on the health supplement industry, indicating a sustained growth trend in the medium to long term [2][3]. Core Insights - The health supplement market in China is projected to grow from CNY 321.37 billion in 2020 to CNY 415.03 billion by 2024, with a compound annual growth rate (CAGR) of 6.60%, making it the second-largest market globally after the United States [2][3]. - Per capita consumption in China is approximately one-fifth of that in mature markets like Australia, South Korea, and the United States, indicating significant growth potential [3][20]. - The penetration rate among the elderly population (aged 65 and above) in China is only 23.04%, compared to 73.04% in the U.S., suggesting a 2-3 times growth opportunity [3][20]. - The industry is characterized by a diverse range of upstream raw materials, with concentrated production capacity in certain segments, while downstream companies exhibit relatively strong profitability and are accelerating international expansion [3][24]. Summary by Sections Industry Development and Outlook - The health supplement industry in China is expected to maintain a growth trend, with market size projected to reach CNY 447.3 billion by 2029 [16][20]. - The dual-track registration and filing system for health supplements has been implemented, easing industry entry barriers [16][17]. Industry Chain - Upstream: The variety of raw materials includes vitamins, minerals, amino acids, extracts, and probiotics, with some production concentrated among a few key players [24]. - Downstream: Companies often overlap in production and brand marketing, with low sensitivity to cost changes, allowing them to enjoy high added value through premium pricing [3][24][31]. Sales Channels - E-commerce is the primary sales channel, expected to account for 43.9% of sales by 2024, while traditional channels face challenges [4][24]. Key Companies - **Tongrentang**: A leading brand in the VDS segment, focusing on scientific nutrition and maintaining a market share above the industry average [5][32]. - **Jindaiwei**: A company with a full industry chain layout, emphasizing core raw material advantages and international brand localization [9][32]. - **Xianle Health**: A CDMO leader with multi-formulation development capabilities, covering markets in China, the U.S., and Europe [9][32].

Core Viewpoint - Jindawei's stock price has shown significant growth this year, with a year-to-date increase of 44.01%, indicating strong market performance and investor interest [1][2]. Financial Performance - For the first half of 2025, Jindawei achieved a revenue of 1.728 billion yuan, representing a year-on-year growth of 13.46% [2]. - The net profit attributable to shareholders for the same period was 247 million yuan, reflecting a substantial increase of 90.12% year-on-year [2]. Stock Market Activity - As of October 20, Jindawei's stock price was 21.17 yuan per share, with a trading volume of 123 million yuan and a turnover rate of 0.94% [1]. - The company experienced a net outflow of main funds amounting to 8.2525 million yuan, with significant selling pressure observed [1]. Shareholder Information - As of June 30, 2025, the number of Jindawei shareholders was 40,700, a decrease of 4.30% from the previous period [2]. - The average number of circulating shares per shareholder increased by 4.50% to 14,976 shares [2]. Dividend Distribution - Since its A-share listing, Jindawei has distributed a total of 2.761 billion yuan in dividends, with 488 million yuan distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth-largest circulating shareholder, holding 6.9372 million shares, an increase of 1.5915 million shares from the previous period [3]. - Southern CSI 1000 ETF and Huaxia CSI 1000 ETF also increased their holdings, while Tianhong CSI Food and Beverage ETF exited the top ten circulating shareholders list [3].

Market Overview - The food processing sector increased by 0.49% on October 16, with *ST Chuntian leading the gains [1] - The Shanghai Composite Index closed at 3916.23, up 0.1%, while the Shenzhen Component Index closed at 13086.41, down 0.25% [1] Stock Performance - *ST Chuntian (600381) closed at 4.88, up 4.95% with a trading volume of 89,600 shares and a turnover of 43.38 million yuan [1] - Quandawei (002626) closed at 21.90, up 3.01% with a trading volume of 239,000 shares and a turnover of 52.5 million yuan [1] - Tangchen Beijian (300146) closed at 12.46, up 2.81% with a trading volume of 570,200 shares and a turnover of 714 million yuan [1] - Shuanghui Development (000895) closed at 25.40, up 0.99% with a trading volume of 108,000 shares and a turnover of 274 million yuan [1] - Other notable stocks include Jiaoda Anli (600530) and Chunxue Food (605567), with minor increases of 0.84% and 0.20% respectively [1] Capital Flow - The food processing sector experienced a net outflow of 106 million yuan from institutional investors, while retail investors saw a net inflow of 69.89 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2] Individual Stock Capital Flow - Anjiu Food (603345) had a net inflow of 18.59 million yuan from institutional investors, while retail investors had a net outflow of 34.42 million yuan [3] - Jiaoda Anli (600530) saw a net inflow of 16.91 million yuan from institutional investors, but retail investors had a net outflow of 9.50 million yuan [3] - *ST Chuntian (600381) had a net inflow of 11.76 million yuan from institutional investors, with retail investors also experiencing a net outflow [3]

Core Viewpoint - The report from Tianfeng Securities highlights that Jindawei's main business includes health products, coenzyme Q10, and vitamin series, with a projected revenue of 1.728 billion yuan in H1 2025, representing a year-on-year increase of 13.5%, and a net profit attributable to the parent company of 247 million yuan, reflecting a significant year-on-year growth of 90.1% [1] Group 1: Company Performance - The health product market is continuously expanding, driven by increasing health consumption demand [1] - In the short term, the company expects stable growth in coenzyme Q10 and a surge in domestic demand for its health product brand, Duote Beisi, indicating a continuation of high growth in H1 2025 [1] - For the medium to long term, the company has a clear growth path, leveraging its synthetic biology technology platform to incubate high-value new products like EPA, potentially replicating the success of coenzyme Q10 [1] Group 2: Investment and Growth Projections - The company plans to use funds from convertible bonds for the expansion and renovation of coenzyme Q10 production, as well as projects for 30,000 tons of allulose and 5,000 tons of inositol, which are expected to provide new growth points for performance [1] - The brandization of the company's health products is also undergoing continuous upgrades and implementation [1] - Projected net profits attributable to the parent company for 2025-2027 are estimated at 440 million, 650 million, and 790 million yuan, with growth rates of 29%, 47%, and 22% respectively [1] Group 3: Valuation and Market Position - The company is compared to peers such as Tongrentang and Ruoyuchen, with a PEG ratio of 1.1 for 2026, corresponding to a PE of 35X [1] - The target market value is set at 15.7 billion yuan, with a target price of 25.7 yuan, maintaining a "buy" rating [1]